Navigation Links
New Data Presented on Micardis (Telmisartan) Tablets in,Hypertensive Patients With Type 2 Diabetes

observational studies investigating the effects of Micardis (telmisartan) compared with other treatments, including other available ARBs, for hypertension. Note that these trials were investigational and were conducted to expand scientific knowledge of Micardis (telmisartan). These trials include treatment for conditions outside of the approved indications for Micardis (telmisartan).

*A prospective, randomised, double-blind, double-dummy, forced-titration, multicenter, parallel group, 1-year treatment trial to compare telMisartan 40 mg titrated to 80 mg versus losArtan 50 mg titrated to 100 mg, in hypertensive type 2 DiabEtic patients with Overt nephropathy.

About Micardis(R) (telmisartan) tablets

MICARDIS is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension and may be used alone or in combination with other antihypertensive agents. In the clinical trial programs PROTECTION, ONTARGET and PRoFESS, over 58,000 patients have been enrolled to investigate the cardiovascular protective effects of MICARDIS.

For more information and full prescribing information, please visit www.MICARDIS.com


    Safety Information


USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS Tablets should be discontinued as soon as possible (see WARNINGS, Fetal/Neonatal Morbidity and Mortality).

MICARDIS is indicated for the treatment of hypertension.

MICARDIS is contraindicated in patients who are hypersensitive to any of its components.

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those receiving high doses of diuretics), symptomatic hypotension may occur after initiation of MICARDIS therapy.
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
Post Your Comments:
(Date:8/27/2014)... By now, if you haven,t heard about the ALS Ice ... awareness campaign has brought this devastating disease to the forefront ... Million (and counting) for ALS. Every day, more and more ... as well. One such company, Acorn Stairlifts Inc., ... works with ALS sufferers and helps to provide solutions for ...
(Date:8/27/2014)... 27, 2014  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the Morgan Stanley Global Healthcare Conference on ... You are invited to listen to the live discussion ... access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP .  A recorded ... after conclusion of the live event and accessible at ...
(Date:8/27/2014)... 2014 North American lighting leader OSRAM SYLVANIA ... for the new OSRAM ITOS ® PHASER ® ... for microscopy, endoscopy and surgical head lamps that delivers the ... and lamp life. "We,re honored to be recognized ... innovative new technologies of the past year," said Andreas ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
(Date:8/27/2014)... Sound Telecom, a leading telecommunications company ... business communication systems, has unveiled an article titled “ ... Text Messaging .” The piece examines the world of ... to remain compliant with HIPAA and HITECH requirements. ... C.O.O. at Sound Telecom, opens with evidence that the ...
(Date:8/27/2014)... Morristown,NJ (PRWEB) August 27, 2014 ... NovoTTF-100A System, a ground breaking anti-cancer therapy for the ... now certified to prescribe this new medical therapy and ... GBM patients starting immediately. , NovoTTF™ Therapy is a ... GBM patients 22 years of age and older. It ...
(Date:8/27/2014)... August 27, 2014 Parker Waichman LLP, ... rights of victims injured by defective medical devices, reports ... for discovery procedures, specifically Collection and Preservation of Evidence, ... transvaginal mesh devices. (MDL No. 2187, In Re: C.R. ... United States District Court, Southern District or West Virginia; ...
(Date:8/27/2014)... August 27, 2014 As medical marijuana ... big business has taken notice. With 23 states and ... cannabis friendly legislation on their books the time for ... as New York and Florida are in the process ... laws a void of reliable information and services has ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- Pouring half a glass of wine ... to a new study. Researchers asked 74 college students and ... from bottles that had varying amounts of wine in them. The ... Those who had a "rule of thumb" about how much to ... two fingers from the top -- poured less wine than those ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 2Health News:Sound Telecom Releases Article on Secure Messaging with Huge Implications for the Healthcare Industry 3Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 2Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4Health News:The Marijuana Real Estate Market Opens Up 2Health News:The Marijuana Real Estate Market Opens Up 3Health News:'Half a Glass' Rule May Curb Overdrinking 2
... HOLLYWOOD, Calif., Oct. 14 Kerby T.,Alvy, Ph.D., the ... in North Hollywood (CICC), has been invited by the ... an expert to inform the,development of CDC,s strategic framework ... focuses on safe, stable, nurturing relationships,(SSNR) as the foundation ...
... Friday with one-of-a-kind wrapped bus featuring candidates, ,healthcare report ... star Donna Smith, local activists pledge to educate voters on ... presidential candidates, healthcare proposals, LAS VEGAS, Oct. ... Nevada and around the country launched a drive,to make sure ...
... Society, the largest non-government, not-for-profit funding source of cancer ... research and training grants totaling more than $54 million ... The grants are the first under a new realignment ... training. All of the grants go into effect January ...
... macular degeneration, study finds , , TUESDAY, Oct. 14 ... Florida or Arizona for health reasons, be sure to ... new study that found that older people with low ... vegetables, and who are exposed to short-wavelength blue light ...
... drive revenues, according to Millennium ... Research Group, ... for Soft Tissue Repair 2009 report, the,US market for ventral hernia repair ... $825 million over the next five years. This market,comprises both synthetic mesh ...
... Versus a Year Ago; EPS was $1.17, Excluding ... NEW BRUNSWICK, N.J., Oct. 14 Johnson &,Johnson today ... of,2008, an increase of 6.4% as compared to the ... positive impact of currency was 3.1%.,Domestic sales were up ...
Cached Medicine News:Health News:Los Angeles Psychologist to Help CDC Fight Child Abuse 2Health News:National RN Union Launches Multi-State Drive for Healthcare Voters With Road Show in Nevada, October 13 Through 17 2Health News:American Cancer Society awards research grants to 116 investigators at 75 institutions nationwide 2Health News:American Cancer Society awards research grants to 116 investigators at 75 institutions nationwide 3Health News:American Cancer Society awards research grants to 116 investigators at 75 institutions nationwide 4Health News:Too Much Sun, Too Few Antioxidants Spell Eye Trouble 2Health News:Too Much Sun, Too Few Antioxidants Spell Eye Trouble 3Health News:Ventral Hernia Repair Market to Grow to Over $800 Million in 2013 2Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 2Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 3Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 4Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 5Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 6Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 7Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 8Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 9Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 10Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 11Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 12Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 13Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 14Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 15Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 16Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 17Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 18Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 19Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 20Health News:Johnson & Johnson Reports 2008 Third-Quarter Results: 21
Puros allografts is a family of bone products specially designed and processed to meet the demanding needs of spine surgeons. The grafts are processed using the proprietary Tutoplast process....
... Graftech cervical dowels are ... to graft expulsion and improve ... allows immediate red blood cell ... Grafton DBM gel into the ...
8 mm S Graftech cervical spacer....
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Medicine Products: